Amy Mcbride Wendell Purchases 5,000 Shares of AxoGen, Inc Common Stock (AXGN) Stock
AxoGen, Inc Common Stock (NASDAQ:AXGN) Director Amy Mcbride Wendell acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average cost of $36.89 per share, with a total value of $184,450.00. Following the purchase, the director now directly owns 18,333 shares in the company, valued at approximately $676,304.37. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
AxoGen, Inc Common Stock stock opened at $37.75 on Friday. AxoGen, Inc Common Stock has a 52 week low of $15.10 and a 52 week high of $56.85. The company has a market capitalization of $1.47 billion, a P/E ratio of -121.77 and a beta of 0.01.
AxoGen, Inc Common Stock (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). AxoGen, Inc Common Stock had a negative return on equity of 26.50% and a negative net margin of 24.96%. The firm had revenue of $20.58 million during the quarter, compared to analyst estimates of $21.25 million. During the same period in the prior year, the business posted ($0.04) EPS. The company’s revenue for the quarter was up 35.7% on a year-over-year basis. analysts forecast that AxoGen, Inc Common Stock will post -0.61 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the business. Pier Capital LLC acquired a new stake in shares of AxoGen, Inc Common Stock during the 2nd quarter valued at $7,670,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of AxoGen, Inc Common Stock during the 2nd quarter valued at $156,000. Brown Advisory Inc. acquired a new stake in shares of AxoGen, Inc Common Stock during the 1st quarter valued at $215,000. UBS Group AG boosted its stake in shares of AxoGen, Inc Common Stock by 43.8% during the 1st quarter. UBS Group AG now owns 26,396 shares of the medical equipment provider’s stock valued at $964,000 after buying an additional 8,036 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of AxoGen, Inc Common Stock by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after buying an additional 1,345 shares during the period. 71.18% of the stock is owned by institutional investors.
AxoGen, Inc Common Stock Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.